March 23, 2020
Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors.
March 2, 2020
Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two conferences in March, 2020.
January 6, 2020
Carisma Therapeutics expands leadership with appointments of Debora Barton, MD as Chief Medical Officer, and Tom Wilton as Chief Business Officer.
November 18, 2019
Carisma Therapeutics Senior Scientist Konrad Gabrusiewicz, PhD, will present an abstract titled "CT-0508, a novel CAR macrophage product directed against HER2, promotes a pro-inflammatory tumor microenvironment" at the AACR Tumor Immunology and Immunotherapy 2019 meeting taking place November 17-20 in Boston, MA.
November 16, 2019
Carisma Therapeutics announced today that it will be participating in three upcoming investor conferences.
October 21, 2019
Carisma's VP of Business Development, Dora Mitchell, PhD and VP of Discovery Research, Michael Klichinsky, PharmD, PhD chaired and presented at the inaugural macrophage-directed therapies summit taking place October 22-24, 2019 in Boston, MA.